China Medical Technologies to Announce Financial Results for the Third Quarter Ended December 31, 2007 on February 28, 2008

BEIJING, Jan. 29 China MedicalTechnologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-basedmedical device company that develops, manufactures and markets advanced in-vitro diagnostic products and high intensity focused ultrasound tumor therapysystems, today announces that it will report its unaudited financial resultsfor the third quarter ended December 31, 2007 ("3Q FY2007") after the U.S.market closes on February 28, 2008. The Company's 2007 fiscal year ends onMarch 31, 2008. The Company's management will host an earnings conferencecall at 8:00 p.m., Eastern Time on the same day of the earnings announcement(9:00 a.m. on February 29, 2008 Beijing/Hong Kong time).

A live webcast of the conference call will be available onhttp://ir.chinameditech.com .

A replay of this webcast will be available for one month on this website.

A telephone replay of the call will be available after the conclusion ofthe conference call through 10:00 p.m. Eastern Time on February 29, 2008. Thedial-in details for the replay are as follows:

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device companythat develops, manufactures and markets advanced in-vitro diagnostic productsusing Enhanced Chemiluminescence (ECLIA) technology and Fluorescent in situHybridization (FISH) technology, to detect and monitor various diseases anddisorders, and products using High Intensity Focused Ultrasound (HIFU) for thetreatment of solid cancers and benign tumors. For more information, pleasevisit http://www.chinameditech.com .Conference Call The dial-in details for the live conference call are as follows: -- U.S. Toll Free Number 1-866-700-7101 -- International dial-in number 1-617-213-8837 Passcode: CMEDCALL.

SOURCE China Medical Technologies, Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...